Q2 2024 EPS Estimates for Bio-Path Holdings, Inc. Lifted by Analyst (NASDAQ:BPTH)

Bio-Path Holdings, Inc. (NASDAQ:BPTH) – Investment analysts at Roth Capital boosted their Q2 2024 earnings estimates for Bio-Path in a research note issued on Monday, June 17th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($1.54) for the quarter, up from their prior estimate of ($2.06). The consensus estimate for Bio-Path’s current full-year earnings is ($9.68) per share. Roth Capital also issued estimates for Bio-Path’s Q3 2024 earnings at ($0.93) EPS, Q4 2024 earnings at ($0.93) EPS, FY2024 earnings at ($5.53) EPS, FY2025 earnings at ($3.65) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($3.40) EPS and FY2028 earnings at $5.19 EPS.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.54) by ($0.34).

Several other equities research analysts also recently issued reports on BPTH. Roth Mkm reaffirmed a “buy” rating and set a $40.00 price target on shares of Bio-Path in a research note on Thursday, April 18th. StockNews.com started coverage on shares of Bio-Path in a research report on Thursday, May 2nd. They issued a “sell” rating for the company.

Bio-Path Stock Performance

NASDAQ:BPTH opened at $2.27 on Wednesday. Bio-Path has a twelve month low of $1.85 and a twelve month high of $44.80. The firm’s fifty day simple moving average is $2.62 and its 200 day simple moving average is $6.00.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.